Step 1 of 2
Explore current and emerging evidence for TROP2-directed ADCs in triple-negative breast cancer, including first-line treatment for patients who are not candidates for immunotherapy and later-line sequencing. Review individualized treatment selection and multidisciplinary prevention and management of ADC-associated toxicities.